

Conditions (Specific Gene if Applicable)	Study Type	Phases	Interventions	Age	Gender	Title	Acronym	Status	Start Date	First Posted	Last Update	Primary Completion	Completion	URL	Locations
Achromatopsia (CNG3, CNGB3)	Interventional	Phase 1 Phase 2	Gene Therapy: rAAV-CNGB3 or rAAV-CNG3	3 Years to 100 Years	All	Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNG3		Active, not recruiting	06/29/17	09/12/17	01/14/22	01/15/26	01/15/26	<a href="https://clinicaltrials.gov/show/study/NCT03278873">https://clinicaltrials.gov/show/study/NCT03278873</a>	Kellogg Eye Center, Ann Arbor, Michigan, United States Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom University of California, San Francisco, San Francisco, California, United States Vitreoretinal Associates, Gainesville, Florida, United States Bascom Palmer Eye Institute, Miami, Florida, United States Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States Boston Children's Hospital, Boston, Massachusetts, United States Columbia College of Physicians and Surgeons, New York, New York, United States Cincinnati Eye Institute, Cincinnati, Ohio, United States Casey Eye Institute, Oregon Health and Sciences University, Portland, Oregon, United States Baylor College of Medicine, Houston, Texas, United States University of Wisconsin, McPherson Eye Research Institute, Madison, Wisconsin, United States Hadassah-Hebrew University Medical Center, Jerusalem, Israel
Achromatopsia (CNG3)	Interventional	Phase 1 Phase 2	Gene Therapy: AGTC-402	4 Years and older	All	Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNG3A Chromatopsia		Recruiting	05/01/17	10/17/16	04/06/21	09/01/21	09/01/25	<a href="https://clinicaltrials.gov/show/study/NCT02935517">https://clinicaltrials.gov/show/study/NCT02935517</a>	University of California, San Francisco, San Francisco, California, United States Vitreoretinal Associates, Gainesville, Florida, United States Bascom Palmer Eye Institute, Miami, Florida, United States Pangere Center for Inherited Retinal Diseases, The Chicago Lighthouse for People Who Are Blind or Visually Imp, Chicago, Illinois, United States Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States Boston Children's Hospital, Boston, Massachusetts, United States Columbia College of Physicians and Surgeons, New York, New York, United States Cincinnati Eye Institute, Cincinnati, Ohio, United States Casey Eye Institute, Oregon Health and Sciences University, Portland, Oregon, United States Baylor College of Medicine, Houston, Texas, United States University of Wisconsin, McPherson Eye Research Institute, Madison, Wisconsin, United States Hadassah-Hebrew University Medical Center, Jerusalem, Israel
Achromatopsia (CNGB3)	Interventional	Phase 1 Phase 2	Gene Therapy: rAAV2YF-PRL7-hCNGB3	4 Years and older	All	Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia		Recruiting	02/01/16	11/09/15	04/06/21	09/01/21	09/01/25	<a href="https://clinicaltrials.gov/show/study/NCT02599922">https://clinicaltrials.gov/show/study/NCT02599922</a>	University of California, San Francisco, San Francisco, California, United States Vitreoretinal Associates, Gainesville, Florida, United States Bascom Palmer Eye Institute, Miami, Florida, United States Pangere Center for Inherited Retinal Diseases, The Chicago Lighthouse for People Who Are Blind or Visually Imp, Chicago, Illinois, United States Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States Boston Children's Hospital, Boston, Massachusetts, United States Columbia College of Physicians and Surgeons, New York, New York, United States Cincinnati Eye Institute, Cincinnati, Ohio, United States Casey Eye Institute, Oregon Health and Sciences University, Portland, Oregon, United States Baylor College of Medicine, Houston, Texas, United States University of Wisconsin, McPherson Eye Research Institute, Madison, Wisconsin, United States Hadassah-Hebrew University Medical Center, Jerusalem, Israel
Aicardi Syndrome	Observational			All Ages	All	Study of Selected X-Linked Disorders: Aicardi Syndrome		Recruiting	10/01/02	06/13/08	03/05/21	01/01/25	01/01/25	<a href="https://clinicaltrials.gov/show/study/NCT00627411">https://clinicaltrials.gov/show/study/NCT00627411</a>	Baylor College of Medicine, Houston, Texas, United States
Aicardi Syndrome	Observational			All Ages	All	Brain Development Research Program		Recruiting	08/01/09	03/21/06	06/30/21	01/01/25	01/01/25	<a href="https://clinicaltrials.gov/show/study/NCT00305305">https://clinicaltrials.gov/show/study/NCT00305305</a>	University of California, San Francisco, San Francisco, California, United States
Bardet-Bied Syndrome	Observational			All Ages	All	Clinical Registry Investigating Bardet-Bied Syndrome	CRIBS	Recruiting	06/01/14	12/31/14	03/02/22	12/01/26	12/01/26	<a href="https://clinicaltrials.gov/show/study/NCT03192510">https://clinicaltrials.gov/show/study/NCT03192510</a>	Macfarland Clinic, Research Foundation, Marshfield, Wisconsin, United States
Best disease   Autosomal Dominant Vitreoretinopathies choroidopathy	Observational			5 Years and older	All	Stem Cell Models of Best Disease and Other Retinal Degenerative Diseases.		Active, not recruiting	02/01/04	06/13/14	01/06/22	12/01/23	12/01/23	<a href="https://clinicaltrials.gov/show/study/NCT02162953">https://clinicaltrials.gov/show/study/NCT02162953</a>	Mayo Clinic, Rochester, Minnesota, United States
Chediak-Higashi Syndrome	Observational			1 Month to 70 Years	All	Study of Chediak-Higashi Syndrome		Recruiting	09/10/02	06/19/00	03/02/22			<a href="https://clinicaltrials.gov/show/study/NCT00059137">https://clinicaltrials.gov/show/study/NCT00059137</a>	National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Chronic Progressive External Ophthalmoplegia   Kearns-Saure CLN3-related Disorders	Interventional	Not Applicable	Device: OrCam MyEye 2	6 Years to 18 Years	All	Optic-to-Audio Device in a Pediatric Cohort With CLN3-related Conditions or Low Vision		Recruiting	03/01/22	08/19/21	01/31/22	12/01/23	12/01/23	<a href="https://clinicaltrials.gov/show/study/NCT05121358">https://clinicaltrials.gov/show/study/NCT05121358</a>	Mayo Clinic, Rochester, Minnesota, United States
Congenital cranial dysinnervation disorders	Observational			All Ages	All	Genetic Studies of Strabismus, Congenital Cranial Dysinnervation Disorders (CCDDs), and Their Associated Anomalies		Recruiting	09/30/21	07/23/21	10/07/21	01/20/25	01/20/25	<a href="https://clinicaltrials.gov/show/study/NCT04974307">https://clinicaltrials.gov/show/study/NCT04974307</a>	National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Genetic Eye Diseases	Observational			All Ages	All	Genetics of Inherited Eye Disease		Recruiting	02/01/04	02/31/17	09/10/21	01/01/27	01/01/27	<a href="https://clinicaltrials.gov/show/study/NCT00259430">https://clinicaltrials.gov/show/study/NCT00259430</a>	Boston Children's Hospital, Boston, Massachusetts, United States
Genetic Eye Diseases	Observational			1 Year and older	All	Whole Exome and Whole Genome Sequencing for Genotyping of Inherited and Congenital Eye Conditions		Recruiting	06/22/15	06/15/15	11/24/21	09/01/23	09/01/23	<a href="https://clinicaltrials.gov/show/study/NCT02312187">https://clinicaltrials.gov/show/study/NCT02312187</a>	National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Hermansky-Pudlak Syndrome	Observational			1 Month and older	All	Clinical and Basic Investigations into Hermansky-Pudlak Syndrome		Recruiting	08/05/14	03/04/14	03/09/22	08/05/25	08/05/25	<a href="https://clinicaltrials.gov/show/study/NCT02707894">https://clinicaltrials.gov/show/study/NCT02707894</a>	National Institutes of Health Clinical Center, Bethesda, Maryland, United States
								Recruiting	11/06/95	11/04/99	03/02/22			<a href="https://clinicaltrials.gov/show/study/NCT00014656">https://clinicaltrials.gov/show/study/NCT00014656</a>	National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States University of California, San Diego, La Jolla, California, United States University of California, Los Angeles, Los Angeles, California, United States National Institutes of Health Clinical Center, Bethesda, Maryland, United States Zhongshan Ophthalmic Center, Guangzhou, China Seconde Universita di Napoli, Napoli, Italy University of the Punjab, Lahore, Pakistan University of the Philippines, Manila, Philippines The National Academy of Sciences of Ukraine, Odessa, Ukraine
Inherited Eye Diseases	Observational			4 Years and older	All	Clinical and Molecular Studies in Families With Inherited Eye Disease		Recruiting	10/04/16	05/13/16	03/03/22	01/01/23	01/01/23	<a href="https://clinicaltrials.gov/show/study/NCT02712136">https://clinicaltrials.gov/show/study/NCT02712136</a>	Foundation Fighting Blindness, Columbia, Maryland, United States
Inherited Eye Diseases	Observational			All Ages	All	Inherited Retinal Degenerative Disease Registry	MRTR	Recruiting	06/01/15	05/06/15	05/04/21	06/01/37	06/01/37	<a href="https://clinicaltrials.gov/show/study/NCT02335940">https://clinicaltrials.gov/show/study/NCT02335940</a>	University of California, San Francisco, San Francisco, California, United States National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Inherited Eye Diseases	Observational			2 Years and older	All	Repository for Inherited Eye Diseases		Active, not recruiting	09/20/06	09/21/06	03/07/22			<a href="https://clinicaltrials.gov/show/study/NCT03178242">https://clinicaltrials.gov/show/study/NCT03178242</a>	University of Iowa, Iowa City, Iowa, United States Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania, United States Ghent University Hospital and Ghent University, Ghent, Belgium
Leber Congenital Amaurosis, Type 10 (CEP290)	Interventional	Phase 1 Phase 2	Drug: QR-110	6 Years and older	All	Extension Study to Study PQ-110-001 (NCT03140969)	INSIGHT	Active, not recruiting	05/13/19	04/12/19	02/09/22	05/01/23	05/01/23	<a href="https://clinicaltrials.gov/show/study/NCT03913130">https://clinicaltrials.gov/show/study/NCT03913130</a>	University of Miami - Bascom Palmer Eye Institute, Miami, Florida, United States University of Iowa, Iowa City, Iowa, United States Columbia University Medical Center, New York, New York, United States Casey Eye Institute - Oregon Health & Science University, Portland, Oregon, United States University of Pennsylvania - Center for Advanced Retinal & Ocular Therapeutics, Philadelphia, Pennsylvania, United States Baylor College of Medicine, Houston, Texas, United States University of Wisconsin Zekherun Genet (UZ), Ghent, Belgium HRET - CHA-nica Santa Casa de Misericórdia de Belo Horizonte, Belo Horizonte, MG, Brazil Federal University of São Paulo - Hospital São Paulo (UNESP-HSP), São Paulo, SP, Brazil The Hospital for Sick Children - SickKids, Toronto, Canada McGill University Health Centre - Centre for Innovative Medicine, Montreal, Quebec, Canada Centre de maladies rares CHMO des Quinze Vingts, Paris, France Hopital Civil de Strasbourg, Strasbourg, France Justus Liebig Universitäts - Department of Ophthalmology, Gießen, Germany University of Tuebingen - Inst. for Ophthalmic Research, Tuebingen, Germany Eye Clinic University of Campania Luigi Vanvitelli, Naples, Italy Amsterdam University Medical Center - Locatie AMC, Amsterdam, Netherlands Radboud University Medical Centrum, Nijmegen, Netherlands Het Oogziekenhuis Rotterdam, Rotterdam, Netherlands Moorfields Eye Hospital - NHS Foundation Trust, London, United Kingdom
Leber Congenital Amaurosis, Type 10 (CEP290)	Interventional	Phase 2 Phase 3	Drug: Sepofarsen	8 Years and older	All	A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10	ILLUMINATE	Active, not recruiting	04/04/19	04/12/19	01/11/21	12/01/21	12/01/21	<a href="https://clinicaltrials.gov/show/study/NCT03913133">https://clinicaltrials.gov/show/study/NCT03913133</a>	Bascom Palmer Eye Institute, Miami, Florida, United States Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States W.K. Kellogg Eye Center - University of Michigan, Ann Arbor, Michigan, United States Casey Eye Institute - OHSU, Portland, Oregon, United States
Leber Congenital Amaurosis, Type 10 (CEP290)	Interventional	Phase 1 Phase 2	Drug: EDIT-101	3 Years and older	All	Single Ascending Dose Study in Participants With LCA10		Recruiting	09/26/19	03/13/19	10/18/21	03/21/24	03/21/24	<a href="https://clinicaltrials.gov/show/study/NCT04374749">https://clinicaltrials.gov/show/study/NCT04374749</a>	Bascom Palmer Eye Institute, Miami, Florida, United States Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States W.K. Kellogg Eye Center - University of Michigan, Ann Arbor, Michigan, United States Casey Eye Institute - OHSU, Portland, Oregon, United States Université Pierre et Marie Curie, Paris, France Universitätsklinikum Gießen und Marburg GmbH, Gießen, Germany Radboud University Medical Center, Nijmegen, Gelderland, Netherlands
Leber Congenital Amaurosis, Type 10 (CEP290)	Observational			3 Years to 99 Years	All	Natural History Study of CEP290-Related Retinal Degeneration		Recruiting	12/17/17	01/10/18	02/15/22	03/11/22	03/11/22	<a href="https://clinicaltrials.gov/show/study/NCT03196042">https://clinicaltrials.gov/show/study/NCT03196042</a>	Nijmegen, Gelderland, Netherlands
Leber Congenital Amaurosis, Type 2 (RP65)	Interventional	Phase 1 Phase 2	Gene Therapy: rAAV2-HRPE65v2	8 Years and older	All	Phase 1. Follow-on Study of rAAV2-HRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2		Active, not recruiting	11/01/10	09/24/10	03/12/21	03/01/30	06/01/30	<a href="https://clinicaltrials.gov/show/study/NCT01208389">https://clinicaltrials.gov/show/study/NCT01208389</a>	The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States Doheny Eye Center UCLA, Pasadena, California, United States Emory University Hospital, Atlanta, Georgia, United States Wills Eye Institute, Philadelphia, Pennsylvania, United States CHNO Les Quinze Vingts, Paris, France LMU Klinikum der Universität München / Friedrich-Baur-Institut, Munich, Germany Ospedale Bellaria, Bologna, Italy Moorfields Eye Hospital, London, Greater London, United Kingdom
Leber Hereditary Optic Neuropathy	Interventional	Phase 3	Gene Therapy: GS010	15 Years and older	All	RESCUE and REVERSE Long-term Follow-up	RESCUE/REVERSE	Active, not recruiting	01/09/18	01/23/18	02/04/21	07/01/22	08/01/22	<a href="https://clinicaltrials.gov/show/study/NCT03406104">https://clinicaltrials.gov/show/study/NCT03406104</a>	Doheny Eye Center UCLA Pasadena, Pasadena, California, United States University of Colorado Health Eye Center, Aurora, Colorado, United States Emory Healthcare - The Emory Clinic, Atlanta, Georgia, United States Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States Johns Hopkins University School of Medicine at Mount Sinai, New York, New York, United States Ocular Oncology Service, Philadelphia, Pennsylvania, United States Vanderbilt Eye Institute, Nashville, Tennessee, United States University of Wisconsin Zekherun Genet (UZ), Ghent, Belgium HRET - CHA-nica Santa Casa de Misericórdia de Belo Horizonte, Belo Horizonte, MG, Brazil Federal University of São Paulo - Hospital São Paulo (UNESP-HSP), São Paulo, SP, Brazil The Hospital for Sick Children - SickKids, Toronto, Canada McGill University Health Centre - Centre for Innovative Medicine, Montreal, Quebec, Canada Centre de maladies rares CHMO des Quinze Vingts, Paris, France Hopital Civil de Strasbourg, Strasbourg, France Justus Liebig Universitäts - Department of Ophthalmology, Gießen, Germany University of Tuebingen - Inst. for Ophthalmic Research, Tuebingen, Germany Eye Clinic University of Campania Luigi Vanvitelli, Naples, Italy Amsterdam University Medical Center - Locatie AMC, Amsterdam, Netherlands Radboud University Medical Centrum, Nijmegen, Netherlands Het Oogziekenhuis Rotterdam, Rotterdam, Netherlands Moorfields Eye Hospital - NHS Foundation Trust, London, United Kingdom
Leber Hereditary Optic Neuropathy	Interventional	Phase 3	Gene Therapy: GS010	15 Years and older	All	Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year	REFLECT LHON	Active, not recruiting	03/12/18	09/26/17	02/08/21	06/30/24	06/30/24	<a href="https://clinicaltrials.gov/show/study/NCT03493524">https://clinicaltrials.gov/show/study/NCT03493524</a>	Bascom Palmer Eye Institute, Miami, Florida, United States
Leber Hereditary Optic Neuropathy	Observational		Gene Therapy: rAAV2-P1ND4v2	1 Year and older	All	Pathogenesis and Genetics of Microphthalmia, Anophthalmia and Uveal Coloboma (MAC)		Recruiting	01/08/13	01/29/13	03/03/22	12/27/27	12/27/27	<a href="https://clinicaltrials.gov/show/study/NCT01778543">https://clinicaltrials.gov/show/study/NCT01778543</a>	National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Microphthalmia   Anophthalmia   Coloboma	Observational			1 Year and older	All	Pathogenesis and Genetics of Microphthalmia, Anophthalmia and Uveal Coloboma (MAC)		Recruiting	01/08/13	01/29/13	03/03/22	12/27/27	12/27/27	<a href="https://clinicaltrials.gov/show/study/NCT01778543">https://clinicaltrials.gov/show/study/NCT01778543</a>	National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Neurofibromatosis Type 1	Interventional	Phase 1 Phase 2	Drug: Selumetinib	3 Years to 21 Years	All	Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma		Active, not recruiting	04/19/10	03/18/10	10/21/21	12/01/25	12/01/25	<a href="https://clinicaltrials.gov/show/study/NCT01089101">https://clinicaltrials.gov/show/study/NCT01089101</a>	Children's Hospital Los Angeles, Los Angeles, California, United States Lucie Packard Children's Hospital Stanford University, Palo Alto, California, United States UCSF Medical Center-Mount Zion, San Francisco, California, United States UCSF Medical Center-Parnassus, San Francisco, California, United States Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States Vanderbilt Eye Institute, Nashville, Tennessee, United States University of Wisconsin Zekherun Genet (UZ), Ghent, Belgium HRET - CHA-nica Santa Casa de Misericórdia de Belo Horizonte, Belo Horizonte, MG, Brazil Federal University of São Paulo - Hospital São Paulo (UNESP-HSP), São Paulo, SP, Brazil The Hospital for Sick Children - SickKids, Toronto, Canada McGill University Health Centre - Centre for Innovative Medicine, Montreal, Quebec, Canada Centre de maladies rares CHMO des Quinze Vingts, Paris, France Hopital Civil de Strasbourg, Strasbourg, France Justus Liebig Universitäts - Department of Ophthalmology, Gießen, Germany University of Tuebingen - Inst. for Ophthalmic Research, Tuebingen, Germany Eye Clinic University of Campania Luigi Vanvitelli, Naples, Italy Amsterdam University Medical Center - Locatie AMC, Amsterdam, Netherlands Radboud University Medical Centrum, Nijmegen, Netherlands Het Oogziekenhuis Rotterdam, Rotterdam, Netherlands Moorfields Eye Hospital - NHS Foundation Trust, London, United Kingdom
Neurofibromatosis Type 1	Observational			2 Years to 65 Years	All	Natural History Study of Patients With Neurofibromatosis Type 1		Active, not recruiting	02/25/08	06/18/09	12/23/21			<a href="https://clinicaltrials.gov/show/study/NCT00242436">https://clinicaltrials.gov/show/study/NCT00242436</a>	Children's Hospital Los Angeles, Los Angeles, California, United States Lucie Packard Children's Hospital Stanford University, Palo Alto, California, United States UCSF Medical Center-Mount Zion, San Francisco, California, United States UCSF Medical Center-Parnassus, San Francisco, California, United States Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States Vanderbilt Eye Institute, Nashville, Tennessee, United States University of Wisconsin Zekherun Genet (UZ), Ghent, Belgium HRET - CHA-nica Santa Casa de Misericórdia de Belo Horizonte, Belo Horizonte, MG, Brazil Federal University of São Paulo - Hospital São Paulo (UNESP-HSP), São Paulo, SP, Brazil The Hospital for Sick Children - SickKids, Toronto, Canada McGill University Health Centre - Centre for Innovative Medicine, Montreal, Quebec, Canada Centre de maladies rares CHMO des Quinze Vingts, Paris, France Hopital Civil de Strasbourg, Strasbourg, France Justus Liebig Universitäts - Department of Ophthalmology, Gießen, Germany University of Tuebingen - Inst. for Ophthalmic Research, Tuebingen, Germany Eye Clinic University of Campania Luigi Vanvitelli, Naples, Italy Amsterdam University Medical Center - Locatie AMC, Amsterdam, Netherlands Radboud University Medical Centrum, Nijmegen, Netherlands Het Oogziekenhuis Rotterdam, Rotterdam, Netherlands Moorfields Eye Hospital - NHS Foundation Trust, London, United Kingdom
Optic atrophy (FOXO3)	Observational			2 Years to 65 Years	All	Natural History Study of FOXO3 Mutation-related Mitochondriopathy		Recruiting	11/03/20	10/09/20	03/08/22	01/01/24	03/01/24	<a href="https://clinicaltrials.gov/show/study/NCT04809129">https://clinicaltrials.gov/show/study/NCT04809129</a>	UMBD Pediatrics, Buffalo, New York, United States
Optic atrophy (SLC25A46)	Observational			2 Years to 65 Years	All	Natural History Study of SLC25A46 Mutation-related Mitochondriopathy		Recruiting	11/03/20	10/20/20	03/08/22	01/01/24	03/01/24	<a href="https://clinicaltrials.gov/show/study/NCT04594590">https://clinicaltrials.gov/show/study/NCT04594590</a>	UMBD Pediatrics, Buffalo, New York, United States
Optic atrophy (SLC25A46)	Observational			2 Years and older	All	Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures		Recruiting	09/27/19	02/19/19	12/16/21	10/30/22	10/30/22	<a href="https://clinicaltrials.gov/show/study/NCT03845218">https://clinicaltrials.gov/show/study/NCT03845218</a>	National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Retinitis Pigmentosa (RPGR)	Observational			5 Years and older	All	Natural History Study of Patients With X-linked Retinal Dysphotoperiation Associated With Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR)		Recruiting	12/19/17	11/21/17	02/25/21	12/30/22	12/30/22	<a href="https://clinicaltrials.gov/show/study/NCT03149242">https://clinicaltrials.gov/show/study/NCT03149242</a>	Shiley Eye Institute - UCSD, La Jolla, California, United States Emory Eye Center, Atlanta, Georgia, United States Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States Kellogg Eye Center, Ann Arbor, Michigan, United States UPMC Eye Center, Pittsburgh, Pennsylvania, United States The Hospital for Sick Children, Toronto, Canada Moorfields Eye Hospital, London, United Kingdom
Retinitis Pigmentosa	Observational			13 Years and older	All	Retinal Imaging in Patients With Inherited Retinal Degenerations		Recruiting	11/01/05	11/16/05	09/29/21	10/01/23	11/01/24	<a href="https://clinicaltrials.gov/show/study/NCT00254605">https://clinicaltrials.gov/show/study/NCT00254605</a>	Department of Ophthalmology Retinal Degenerations Clinic, UCSF, San Francisco, California, United States
Retinitis Pigmentosa (CNGB1)	Observational			All Ages	All	CNGB1 and Allied Disorders		Recruiting	03/14/19	11/20/20	11/01/21	03/01/23	03/01/25	<a href="https://clinicaltrials.gov/show/study/NCT04639635">https://clinicaltrials.gov/show/study/NCT04639635</a>	Dr. Stephen H. Tsang, New York, New York, United States Wills Eye Hospital, Philadelphia, Pennsylvania, United States Institut de la Vision/ Centre du Centre Hospitalier National Ophtalmologique de Quinze Vingts, Paris, France Klinikum der Universität München University Eye Hospital, Ludwig-Maximilians-Universität (LMU) Munich, München, Bavaria, Germany Eberhard Karls Universität Tübingen, Tübingen, Germany Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
Retinitis Pigmentosa (Syndromic)	Observational			All Ages	All	UAH HRFD Core Center: Core A: The Hepato/Renal Fibrocytic Diseases Translational Resource		Recruiting	06/01/11	07/26/11	02/21/21	09/01/22	12/01/22	<a href="https://clinicaltrials.gov/show/study/NCT01401098">https://clinicaltrials.gov/show/study/NCT01401098</a>	Children's National Health System, Washington, District of Columbia, United States Children's Hospital of Los Angeles, Los Angeles, California, United States Bascom Palmer Eye Institute, Miami, Florida, United States University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States Massachusetts Eye and Ear Institute, Boston, Massachusetts, United States Kellogg Eye Center, Ann Arbor, Michigan, United States Cincinnati Eye Institute, Cincinnati, Ohio, United States Casey Eye Institute, Portland, Oregon, United States Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States Scheie Eye Institute, Philadelphia, Pennsylvania, United States Cullen Eye Institute, Houston, Texas, United States
Retinitis Pigmentosa   Leber Congenital Amaurosis (RP65)	Observational		Gene Therapy: rAAV2-HRPE65v2	12 Months and older	All	A Patient Registry Study for Patients Treated With Voretigene Neparvovec in US		Active, not recruiting	01/10/19	07/24/18	10/25/21	06/01/25	06/01/25	<a href="https://clinicaltrials.gov/show/study/NCT03972729">https://clinicaltrials.gov/show/study/NCT03972729</a>	University of Iowa, Iowa City, Iowa, United States Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Retinitis Pigmentosa   Leber Congenital Amaurosis, Type 2 (RP65)	Observational	Phase 3	Gene Therapy: rAAV2-HRPE65v2	3 Years and older	All	Safety and Efficacy Study in Subjects With Congenital Amaurosis		Active, not recruiting	10/01/12	10/02/09	12/13/21	07/01/25	07/01/25	<a href="https://clinicaltrials.gov/show/study/NCT00996093">https://clinicaltrials.gov/show/study/NCT00996093</a>	Shands Children's Hospital, University of Florida, Gainesville, Florida, United States Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania, United States
Retinitis Pigmentosa   Leber Congenital Amaurosis, Type 2 (RP65)	Interventional	Phase 1	Gene Therapy: rAAV2-C8SB-RP65	8 Years and older	All	Phase I Trial of Gene Vector to Patients With Retinal Disease Due to RP65 Mutations	LCA	Active, not recruiting	07/01/07	06/01/07	12/14/21	06/01/26	06/01/26	<a href="https://clinicaltrials.gov/show/study/NCT00815146">https://clinicaltrials.gov/show/study/NCT00815146</a>	Shands Children's Hospital, University of Florida, Gainesville, Florida, United States Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania, United States
Retinitis Pigmentosa   Stargardt's Disease	Observational			5 Years and older	All	Roll and Core Mediated Function in Retinal Disease		Recruiting	03/01/17	03/21/15	03/03/22	12/30/24	12/30/24	<a href="https://clinicaltrials.gov/show/study/NCT04374766">https://clinicaltrials.gov/show/study/NCT04374766</a>	Research Site, Phoenix, Arizona, United States Research Site, San Francisco, California, United States Research Site, Miami, Florida, United States Research Site, New York, New York, United States Research Site, Portland, Oregon, United States Research Site, Dallas, Texas, United States Research Site, Houston, Texas, United States Research Site, Salt Lake City, Utah, United States Research Site, Madison, Wisconsin, United States Research Site, Montreal, Quebec, Canada Research Site, Vancouver, Canada Research Site, Helsinki, Finland Research Site, Montpellier, France Research Site, Bonn, Germany Research Site, Tübingen, Germany Research Site, Leiden, Netherlands Research Site, Nijmegen, Netherlands Research Site, Leeds, United Kingdom Research Site, Manchester, United Kingdom Research Site, Oxford, United Kingdom Research Site, Southampton, United Kingdom
Retinitis Pigmentosa, X-Linked	Observational			7 Years and older	All	Natural History of the Progression of X-Linked Retinitis Pigmentosa	XOLARIS	Active, not recruiting	09/29/17	06/14/21	01/12/22	12/21/22	12/21/22	<a href="https://clinicaltrials.gov/show/study/NCT04926129">https://clinicaltrials.gov/show/study/NCT04926129</a>	University of Colorado, Aurora, Colorado, United States University of Michigan Kellogg Eye Center, Ann Arbor, Michigan, United States Duke University Hospital/Dept. of Ophthalmology, Durham, North Carolina, United States Casey Eye Institute, Oregon Health and Science University, Portland, Oregon, United States Retina Foundation of the Southwest, Dallas, Texas, United States University of Utah John A. Moran Eye Center, Salt Lake City, Utah, United States
Retinitis Pigmentosa, X-Linked	Interventional	Phase 1 Phase 2	Biological: 4D-125 IVT Injection	12 Years and older	Male	4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)		Recruiting	06/09/20	08/18/20	03/04/22	04/01/26	09/01/26	<a href="https://clinicaltrials.gov/show/study/NCT04517149">https://clinicaltrials.gov/show/study/NCT04517149</a>	Duke Eye Center, Duke University Medical Center, Durham, North Carolina, United States Casey Eye Institute, Oregon Health and Sciences University, Portland, Oregon, United States Retina Foundation of the Southwest, Dallas, Texas, United States
Retinitis Pigmentosa, X-Linked	Observational			6 Years and older	Male	Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP)		Recruiting	12/01/17	10/19/17	01/14/21	12/01/21	12/01/21	<a href="https://clinicaltrials.gov/show/study/NCT03114207">https://clinicaltrials.gov/show/study/NCT03114207</a>	Southwest, Dallas, Texas, United States
Retinitis Pigmentosa, X-Linked (															